[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Fan et al., 2019 - Google Patents

Immune checkpoint modulators in cancer immunotherapy: recent advances and combination rationales

Fan et al., 2019

Document ID
10300077629850688147
Author
Fan L
Li Y
Chen J
Zheng Y
Xu X
Publication year
Publication venue
Cancer letters

External Links

Snippet

As a new hallmark of cancer, immune surveillance evading plays a critical role in carcinogenesis. Through modulating the immune checkpoints, immune cells in tumor microenvironment can be harnessed to battle cancer cells. In recent years, the …
Continue reading at www.sciencedirect.com (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Similar Documents

Publication Publication Date Title
Gaynor et al. Immune checkpoint inhibitors: Key trials and an emerging role in breast cancer
Fan et al. Immune checkpoint modulators in cancer immunotherapy: recent advances and combination rationales
Chen et al. Immunotherapy of cancer by targeting regulatory T cells
Sun et al. The rise of NK cell checkpoints as promising therapeutic targets in cancer immunotherapy
Martin-Liberal et al. The expanding role of immunotherapy
Hamid et al. Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy
Postow et al. Immune checkpoint blockade in cancer therapy
Carosella et al. A systematic review of immunotherapy in urologic cancer: evolving roles for targeting of CTLA-4, PD-1/PD-L1, and HLA-G
Haanen et al. Immune checkpoint inhibitors
Wang et al. Immune checkpoint blockade and its combination therapy with small-molecule inhibitors for cancer treatment
Pianko et al. Immune checkpoint blockade for hematologic malignancies: a review
Buqué et al. Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications
Yonezawa et al. Boosting cancer immunotherapy with anti-CD137 antibody therapy
Honeychurch et al. Immuno-regulatory antibodies for the treatment of cancer
Economopoulou et al. The promise of immunotherapy in head and neck squamous cell carcinoma: combinatorial immunotherapy approaches
AU2018277559A1 (en) Compositions comprising a combination of an anti-LAG-3 antibody, a PD-1 pathway inhibitor, and an immunotherapeutic agent
Mehdizadeh et al. Immune checkpoints and cancer development: Therapeutic implications and future directions
Gay et al. Immuno-oncologic approaches: CAR-T cells and checkpoint inhibitors
AU2018351007B2 (en) Treatment of ovarian cancer with anti-CD47 and anti-PD-L1
Sapoznik et al. Novel Anti‐Melanoma Immunotherapies: Disarming Tumor Escape Mechanisms
Borrie et al. T Lymphocyte–Based Cancer Immunotherapeutics
Wang et al. Checkpoint inhibitors in immunotherapy of ovarian cancer
Soiffer et al. Tyrosine kinase inhibitors and immune checkpoint blockade in allogeneic hematopoietic cell transplantation
Davis et al. Costimulatory and coinhibitory immune checkpoint receptors in head and neck cancer: unleashing immune responses through therapeutic combinations
Ryan et al. Enhancing the safety of antibody-based immunomodulatory cancer therapy without compromising therapeutic benefit: Can we have our cake and eat it too?